NeuroVive Pharmaceutical AB (publ) publishes prospectus

On 20 November 2013, the Board of Directors of NeuroVive Pharmaceutical AB
(publ) (“NeuroVive”) decided to execute a rights issue. Coincident with this new
share issue, NeuroVive has published a prospectus today, which has been approved
and registered by the Swedish Financial Supervisory Authority.

Upon full subscription, the Company would raise approximately SEK 75.8 m before
issue expenses. The new issue is guaranteed to 66%, or SEK 50.0 m.
Specific financial information that has not been previously disclosed
The prospectus includes specific financial information regarding equity,
liability and net indebtedness as of 30 November 2013, as well as cash and cash
equivalents as of 8 January 2014, which has not previously been published.

As of 30 November 2013, NeuroVive’s equity was SEK 45,061,000. The Company’s
cash and cash equivalents as of 30 November 2013 were SEK 8,408,000. The
Company’s short-term indebtedness was SEK -7,231,000 net. Long-term indebtedness
was SEK 0. Accordingly, the Company’s net indebtedness was SEK -7,231,000 as of
30 November 2013. Comprehensive information on the Company’s equity,
indebtedness and net indebtedness as of 30 November 2013, is on page 46 of the
prospectus.

As of 30 January 2014, the Company’s cash and cash equivalents were SEK 37.2 m.
The change from 30 November 2013 above is explained by factors including the
Company raising SEK 35 m via a private placement in December 2013, see pages 46
-47 of the prospectus.

Prospectus
Prospectuses and application forms are available for download from the Company’s
website www.neurovive.se/index.php/en/investors/shareholder-reports or from Erik
Penser Bankaktiebolag’s website www.penser.se. An information pack, pre-printed
share issue documentation and covering letter will be sent to direct-registered
shareholders. Nominee-registered shareholders will only receive information
packs and covering letters. Printed prospectuses and application forms are
available to order free of charge via e-mail; emission@penser.se eller or by
mail to Erik Penser Bankaktiebolag, Emissionsavdelningen/NeuroVive, Box 7405,
103 91 Stockholm, Sweden.

Schedule for new share issue
The record date for rights to participation in the share issue is 8 January 2014
Subscription period: 13 - 27 January 2014
Trading in subscription rights: 13 - 22 January 2014

Advisors
The financial adviser to the Company for the forthcoming new share issue is Erik
Penser Bankaktiebolag, which will also serve as issuing house for the new share
issue. The legal adviser to the Company for the forthcoming new share issue is
Advokatfirman Lindahl KB.

About NeuroVive
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of anti-viral indications
(Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for
cellular protection and treating mitochondria-related energy regulation
diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

Media and investor relations questions to:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 6221 or ir@neurovive.com
Please also use the above contact if you wish to arrange an interview with
NeuroVive’s CEO, Mikael Brönnegård.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 6220 (switchboard), Fax: +46 (0)46 888 8348
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information
contained in this news release in accordance with the Swedish Securities Market
Act. This information was provided to the media for publication at 16:45. CEST
on 8 January 2014.